Analyst Perspectives on Supernus Pharmaceuticals Stock
Supernus Pharmaceuticals (NASDAQ:SUPN) has received ratings from 5 analysts in the past three months, reflecting a mix of bullish and bearish views.
Average 12-month price targets are $54.8, with a high of $65.00 and a low of $40.00, marking a 31.1% increase from the previous average of $41.80.
- Average price target: $54.8
- High estimate: $65.00
- Low estimate: $40.00
Author's summary: Analysts provide insights into Supernus Pharmaceuticals stock.